Melius MicroBiomics

Melius MicroBiomics is a Canadian biotechnology company specializing in next-generation live biotherapeutic products (LBPs) for human and animal health. Spun out of the University of British Columbia (UBC) Okanagan, the company utilizes its proprietary GEMM™ (Genetically Engineered Microbial Medicine) platform, which includes BioPersist™ and BioColonize™ technologies, to engineer beneficial bacteria that can survive and thrive in inflamed gut environments. Their lead candidate, EcN:ttr, is a bio-engineered version of E. coli Nissle 1917 designed to maintain metabolic function and adhere to the intestinal mucosa during active inflammation, addressing the limitations of traditional probiotics. Melius is currently advancing its pipeline toward first-in-human clinical trials, having recently received regulatory authorization for clinical evaluation in Australia. The company's technology also has applications in animal health, specifically targeting gut health in livestock and pets.